Table 2 Cannabidiol (CBD) suppository use at both follow-up timepoints
Follow-up: 1 month n = 70 | Follow-up: 2 months n = 37 | |
|---|---|---|
Mean ± SD or n (%) | Mean ± SD or n (%) | |
# of CBD suppositories used | 3.29 ± 2.08 (range: 1–10) | 2.84 ± 1.42 (range: 1–6) |
Timing of suppository use: | ||
Pre-menstruation | 38 (54.3%) | 20 (54.1%) |
During menstruation | 52 (74.3%) | 25 (67.6%) |
Post-menstruation | 8 (11.4%) | 6 (16.2%) |
Continuous use during cycle | 3 (4.3%) | 2 (5.4%) |
Patient global impression of change (PGIC): | ||
Median rating (interquartile range) | 5 (2)a | 5 (1)a |
% Rated ≥ moderate improvement | 51 (72.9%) | 30 (81.1%) |
